If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
Good time to top up.
I sold out before this offer came in putting the proceedes into Sumo, which is up over 20% on my purchase price.
Well done to all those who stayed invested.
Congratulations on this being a ten baggers for you rivaldo. I only discovered SD1 this year, so it'll be a while until it's a ten bagger for me.
Well done Taverham. Are you in Taverham itself (Norfolk)?
Tipped in the online IC today by Simon Thompson with a target price of 95 pence.
Well done to anyone who bought these last year when they were less than £3. Had them a few years ago and sold out at a small profit. Seen it mentioned the shares could be worth £21 in due course. Wonder if a share split could be on the cards. Bought some today.
You've got your answer. Hope you're still in profit.
Held for about 3 years added some more this year - great company with a moat. Just down the road too.
At one time today up by 52 pence.
Tip style
Speculative
Risk rating
High
Timescale
Long Term
Bull points
Rising demand for disinfectant products
Robust barriers to entry
Strong financial track record
Fund manager favourite
Bear points
Competition could intensify with growing global interest in hygiene
Shares are priced for continued excellence
By Harriet Clarfelt
London’s Aim All-Share index has fallen by almost a third over the past three months. But shares in Tristel (TSTL), which are traded on the junior market, remain in positive territory. This can be no coincidence. The group, which was founded in 1993, specialises in infection prevention and contamination control – and its products are in high demand, as countries around the world strive to stop the spread of Covid-19.
TSTL:LSE
Tristel PLC
1mth
Today change
4.82%
Price (GBP)
432.40
Hopefully, concerted efforts will stem the transmission of the novel coronavirus in the months ahead. But, even after this anxious and uncertain period, it seems fair to assume that consumers will maintain extra interest in good hygiene practices. Along with Tristel’s sturdy barriers to entry and strong financial track record, this should position it well to cope with increasing interest in hygiene products.
Besides, Tristel claims a significant competitive advantage. It says it is unique globally in using chlorine dioxide to disinfect medical instruments in hospitals. About four-fifths of group revenues pertain to this practice, which subjects the likes of endoscopes and ultrasound probes to deep, rapid cleaning. Meanwhile, using the same chemistry, Tristel has established a footing in hospital surface disinfection – as well as animal health and in contamination control for critical manufacturing environments.
The group’s economic moat is fortified by the fact that it has various regulatory approvals and a list of proven compatibility with hundreds of medical devices – with equipment manufacturers recommending it as their leading product of choice. These attributes would, arguably, be very difficult to replicate – especially given that Tristel’s expertise is backed up by legal protections. As of last June, it held 277 patents in 36 countries.
In the current climate, it is impossible to say whether analysts’ forecasts will change – regardless of how promising the company’s proposition looks. Still, Tristel has delivered a strong historical performance. Over the past three years, its annual revenue growth has compounded at 15 per cent, while underlying profit has grown at 16 per cent.
The group’s numbers for the six months to December 2019 built upon this strong foundation. Revenues rose by more than a fifth to £14.6m, with underlying pre-tax profits up by a quarter to £3m. The dividend was also up 15 per cent to 2.34p – underpinned by net cash of £4.2m at the period-end even after Tristel paid £0.6m in July to buy the final 80 per cent of ‘Tristel Italia’.
Tristel’s results we
John's Investment Chronicle is a great fan of these shares. He has a monthly double page feature in IC.
I managed to get some late yesterday at 125 pence.
https://www.investegate.co.uk/hutchison-china-medi--hcm-/rns/china-phase-ii-trial-initiation-in-mesothelioma/202003310704011812I/
Surprised no one else saw this announcement, it was the reason for the price rise.
Purchased some more this morning. Looksincreasingly good value at the moment. Their services will still be needed.
Long way to go yet rivaldo. We're not out of this yet.
Buy note in IC.
Infection prevention specialist Tristel (TSTL) is working with Byotrol (BYOT) – a micro-cap provider of antimicrobial technologies – to develop a new surface disinfectant product for hospitals.
TSTL:LSE
Tristel PLC
1mth
Today change
0.11%
Price (GBP)
446.50
The groups have entered into a ‘know-how’ licence and commercial collaboration to develop a longer-lasting version of Tristel's high-end surface disinfectant. Byotrol's technology can make surface disinfectants effective for up to eight hours. This compares with a current 'kill time' of 30-60 seconds. The new formulations that will be supplied and licensed to Tristel will be branded Tristel8.
IC View
Tristel’s management revealed in the same breath that the group is experiencing very strong demand across its markets because of the coronavirus pandemic. It said that as a UK manufacturer with very little exposure to international supply chains, and with adequate productive capacity, it is well positioned to meet the requirements of its customers. In unprecedented and uncertain times, mirrored by volatile markets, Tristel is one of the few to be cleaning up – quite literally. For now, we remain optimistic. At 459p, buy.
jediknight,that intersting because you can't believe any of the trades indicated here
rivaldo, It's marked as unknown trade regarding 'buy' or 'sell'
Very quiet here. What happened to Thomas Browne?
You can't believe any of the indicated buys or sells. I sold a % of another share this morning and it showed up as a buy.
Interesting to see my 'sell' showing as a 'buy'. You can't belive anything any more.